- Home
- CRDL vs SKYE Comparison
CRDL vs SKYE Comparison
Compare CRDL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDL
- SKYE
- Stock Information
- Founded
- CRDL 2017
- SKYE 2012
- Country
- CRDL Canada
- SKYE United States
- Employees
- CRDL N/A
- SKYE N/A
- Industry
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CRDL Health Care
- SKYE Health Care
- Exchange
- CRDL Nasdaq
- SKYE Nasdaq
- Market Cap
- CRDL 80.1M
- SKYE 80.7M
- IPO Year
- CRDL N/A
- SKYE N/A
- Fundamental
- Price
- CRDL $1.45
- SKYE $2.24
- Analyst Decision
- CRDL Strong Buy
- SKYE Buy
- Analyst Count
- CRDL 3
- SKYE 6
- Target Price
- CRDL $9.33
- SKYE $16.60
- AVG Volume (30 Days)
- CRDL 165.3K
- SKYE 235.9K
- Earning Date
- CRDL 05-14-2025
- SKYE 05-08-2025
- Dividend Yield
- CRDL N/A
- SKYE N/A
- EPS Growth
- CRDL N/A
- SKYE N/A
- EPS
- CRDL N/A
- SKYE N/A
- Revenue
- CRDL N/A
- SKYE N/A
- Revenue This Year
- CRDL N/A
- SKYE N/A
- Revenue Next Year
- CRDL N/A
- SKYE N/A
- P/E Ratio
- CRDL N/A
- SKYE N/A
- Revenue Growth
- CRDL N/A
- SKYE N/A
- 52 Week Low
- CRDL $0.77
- SKYE $1.14
- 52 Week High
- CRDL $3.12
- SKYE $12.06
- Technical
- Relative Strength Index (RSI)
- CRDL 74.75
- SKYE 55.49
- Support Level
- CRDL $1.18
- SKYE $1.96
- Resistance Level
- CRDL $1.31
- SKYE $2.45
- Average True Range (ATR)
- CRDL 0.09
- SKYE 0.24
- MACD
- CRDL 0.03
- SKYE 0.02
- Stochastic Oscillator
- CRDL 100.00
- SKYE 68.66
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.